Cell line · CVCL_0021
Papers213
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
41 to 60 of 213
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models. | J Funct Biomater | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Necroptotic signaling orchestrates glioblastoma malignancy and potentiates temozolomide response. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ferroptosis resistance-related TEP1 as a novel prognostic biomarker involved in immune cell infiltration and tumour progression in glioblastoma. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Unveiling the prognostic and immunological role of IFI44 in glioma. | Ann Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell Nucleus Extraction with Cellular Indexing. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Purinergic P2X receptor 7 (P2X7R) inhibition induced cytotoxicity in glioblastoma. | PLoS One | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mechanotransduction-related ferroptosis: Enhancing boron neutron capture therapy efficacy in glioblastoma using a spheroid model. | Mol Ther Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of Extracellular Matrix Protein Fibulin-3 Reduces Immunosuppressive Signaling and Increases Macrophage Activation in Glioblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A phosphoserine phosphatase variant present in the brain of Alzheimer's disease patients favors nuclear mistargeting. | FEBS J | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glioma-Associated Mesenchymal Stromal/Stem Cells Derived Exosomal miR-191 Promotes the Proneural-to-Mesenchymal Transition in Glioblastoma Cells via PTEN/PI3K/AKT Signaling. | Int J Nanomedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| UBE2T-Mediated HP1α Ubiquitination Enhances Nucleolar Function and Promotes the Progression of IDH1/TP53-Mutant Glioma. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Clusterin facilitates glioma progression via BCL2L1-dependent regulation of apoptotic resistance. | Front Mol Neurosci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The alternatively spliced diacylglycerol kinase gamma-Δ exon13 transcript generated under hypoxia promotes glioblastoma progression. | Oncol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Purine metabolism rewiring improves glioblastoma susceptibility to temozolomide treatment. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PGM3 abolishes SREBP-1 activation-hexosamine synthesis feedback regulation to effectively suppress brain tumor growth. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A competition network connects Rab5 and Rab11 GTPases at the surface of endocytic structures. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0021/papers?page=3